Testing urine DNA to decide how often bladder cancer patients need checkups
Tests a urine tumor DNA test to see who can have fewer bladder checks.
Plain-language title generated from the registry record
Registry title: Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Key facts
- Where
- Burlington, United StatesSee the site
Where in United States
- Lahey Hospital and Medical CenterBurlington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lahey Clinic
- Trial code
- NCT07187063
- Record updated
- 3 November 2026
- Original description
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.Read full original descriptionShow less
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Inclusion: AUA high-risk bladder cancer1; Received induction BCG or gemcitabine/docetaxel; Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy).
Exclusion: Prior induction intravesical therapy; Concurrent upper tract disease; High-risk NMIBC within 3 years; Variant histology.